Structural racism and multiple sclerosis are more connected than many realize. In the U.S., Black and Hispanic communities face faster MS progression, worse health outcomes, and higher early mortality compared to white individuals. While often viewed as a disease affecting only white people, MS incidence is actually highest in Black populations. These disparities reflect the biological effects of lived experiences shaped by racism—not innate racial differences. Disparities in the incidence, prevalence and outcomes of multiple sclerosis (MS) exist in the USA, often to the detriment of Black and Hispanic people. Despite the common misconception that MS is a disease of white people, the incidence is highest in Black people. Disability accumulates faster and at younger ages in Black and Hispanic people with MS than in their white counterparts, and MS-related mortality in early and mid-adulthood is highest in Black people. These differences are often erroneously interpreted as evidence of innate racial or ethnic variations. In this Perspective, we demonstrate how race and ethnicity – social constructs with a limited biological basis that are often assigned by systems of power – can influence biology through lived experiences, a phenomenon termed ’embodiment’. We review how downstream consequences of structural racism can lead to biological outcomes strongly associated with MS susceptibility, such as imbalanced immune system development, dysregulated immune responses to the Epstein-Barr virus and childhood obesity. We also consider how inequitable health-care access and quality, combined with the younger age of onset and higher comorbidity burdens, might explain racial and ethnic disparities in MS prognosis. Our proposed conceptual model offers a roadmap for generating knowledge and implementing interventions to narrow racial and ethnic disparities in MS susceptibility and outcomes.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: A.M.L.-G. has received grant support and awards from the Patient-Centered Outcomes Research Institute, the National Multiple Sclerosis Society and Atara Biotherapeutics. She currently serves as a voting member on the California Technology Assessment Forum, a core programme of the Institute for Clinical and Economic Review. E.A.Y. has received payments from Hoffman-LaRoche, Alexion (advisory boards) and Pipeline Therapeutics (Data Safety and Monitoring Board) and research funding from Biogen, the National Multiple Sclerosis Society, the Consortium of Multiple Sclerosis Centers, the Canadian Institutes of Health Research, the National Instiututes of Health, the Ontario Institute for Regenerative Medicine, the Stem Cell Network, Garry Hurvitz Centre for Brain & Mental Health Chase an Idea, the SickKids Foundation, the Rare Diseases Foundation, the Multiple Sclerosis Scientific Research Foundation, Canada’s Drug Agency, the McLaughlin Centre, the Leong Center, the Peterson Foundation and the Centre for Brain & Mental Health, and is Co-Editor in Chief of Multiple Sclerosis and Related Disorders. T.J.C.-R., J.B.T. and T.E.G. declare no competing interests.
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Jessica Wilson
- Subash Kafle














